Login to Your Account

Psioxus inks $936M preclinical oncolytic virus deal with BMS

By Nuala Moran
Staff Writer

Tuesday, December 20, 2016

LONDON – Psioxus Therapeutics Ltd. has signed a potential $936 million deal with BMS for NG-348, an armed oncolytic virus that delivers the genes for two T-cell mobilizing proteins.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription